^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABO2011

    i
    Other names: ABO2011, ABOD2011, IL-12 mRNA
    Associations

    News

    Trials
    Company:
    Suzhou Abogen Biosci
    Drug class:
    IL-12 modulator
    Related drugs:
    Associations

    News

    Trials
    5ms
    Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=218, Recruiting, Suzhou Abogen Biosciences Co., Ltd. | N=160 --> 218 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Loqtorzi (toripalimab-tpzi) • ABO2011
    8ms
    Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=160, Recruiting, Suzhou Abogen Biosciences Co., Ltd. | Enrolling by invitation --> Recruiting | Phase classification: P1 --> P1/2 | N=40 --> 160 | Trial completion date: Nov 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2025
    Enrollment status • Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    ABO2011
    1year
    A Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=40, Enrolling by invitation, Suzhou Abogen Biosciences Co., Ltd. | Recruiting --> Enrolling by invitation
    Enrollment status • Metastases
    |
    ABO2011
    over2years
    ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy (clinicaltrials.gov)
    P1, N=60, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IFNG (Interferon, gamma)
    |
    ABO2011
    over2years
    ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P1 trial
    |
    IFNG (Interferon, gamma)
    |
    ABO2011